Form 4: CytomX CFO Christopher Ogden Executes Stock Sale

CFO Christopher Ogden sold 1,624 shares of CytomX Therapeutics to cover tax withholding obligations related to RSU vesting.

Summary

• Christopher Ogden, Chief Financial Officer of CytomX Therapeutics, Inc., sold 1,624 shares of common stock.
• The transaction occurred on June 15, 2026, at a price of $3.05 per share.
• Following the transaction, the reporting person maintains beneficial ownership of 295,324 shares, which includes 167,249 restricted stock units (RSUs).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative to cover tax obligations rather than a discretionary divestment.

Positives

• The sale was non-discretionary and executed solely to satisfy tax withholding obligations associated with the vesting of equity awards.

Negatives

• Reduction in direct equity holdings by a key executive.

Risks

• None identified; this is a routine administrative transaction related to tax compliance.

Future Outlook

Not applicable as this is a mandatory disclosure of an insider transaction.

Industry Context

StockSavvy.ai notes that routine 'sell-to-cover' transactions by executives are standard practice in the biotechnology sector to manage tax liabilities upon the vesting of performance or restricted stock units and do not typically signal a change in management sentiment regarding company prospects.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for executive compensation and tax compliance in the U.S. biotech industry.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was limited in size and purpose.

Key Dates

Keywords

CytomX Therapeutics, CTMX, Insider Trading, Form 4, CFO, Equity Vesting